Seres Therapeutics (NASDAQ:MCRB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “
Separately, BidaskClub cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 7th. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $18.00.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.71) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.73) by $0.02. Seres Therapeutics had a negative return on equity of 103.46% and a negative net margin of 278.44%. The company had revenue of $3.06 million for the quarter, compared to analysts’ expectations of $3.00 million. equities research analysts predict that Seres Therapeutics will post -2.67 EPS for the current year.
Institutional investors and hedge funds have recently bought and sold shares of the company. Voya Investment Management LLC acquired a new stake in shares of Seres Therapeutics during the second quarter worth about $114,000. Cubist Systematic Strategies LLC purchased a new stake in Seres Therapeutics in the 3rd quarter valued at approximately $170,000. Aperio Group LLC purchased a new stake in Seres Therapeutics in the 3rd quarter valued at approximately $191,000. Arrowstreet Capital Limited Partnership purchased a new stake in Seres Therapeutics in the 4th quarter valued at approximately $143,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in Seres Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,270 shares of the biotechnology company’s stock valued at $206,000 after purchasing an additional 2,410 shares in the last quarter. Institutional investors and hedge funds own 81.43% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2018/03/14/zacks-investment-research-upgrades-seres-therapeutics-mcrb-to-hold.html.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.